NCT07241923

A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2070 Injection

A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SYH2070 Injection in Healthy Subjects

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (estimated)
• Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study of SYH2070 injection when administered subcutaneously to healthy subjects.

Conditions

• Healthy Subjects (HS)

Interventions

Type	Name	Description
DRUG	SYH2070 injection	subcutaneous injection
DRUG	Placebo	subcutaneous injection

Timeline

• Start date: 2025-11-15
• Primary completion: 2026-11-01
• Completion: 2027-11-01
• First posted: 2025-11-21
• Last updated: 2025-12-01

Locations

1 site across 1 country: China